Biomarkers in CF, Canada

Registration Status: Pending

Objective: To identify promising novel candidate plasma and sputum biomarkers that indicate acute pulmonary exacerbations in CF. Using a non-targeted approach, we will interrogate the plasma and sputum proteome to discover novel candidate biomarkers that change in levels of expression from stable to exacerbation state. The central hypothesis of this study is that plasma and sputum biomarkers reflective of underlying disease activity can be monitored to diagnose exacerbations.

Registered Biobank Name Biomarkers in CF
Biobank Leader Alicia Murdoch
Country Canada
Email for biobank inquiries amurdoch@providencehealth.bc.ca
Principal Investigator Dr. Bradley Quon
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: